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Pancreatic ductal adenocarcinoma (PDAC) is resis-
tant to most therapies including single-agent immu-
notherapy and has a dense desmoplastic stroma,
and most patients present with advanced metastatic
disease. We reveal that macrophages are the domi-
nant leukocyte population both in human PDAC
stroma and autochthonous models, with an impor-
tant functional contribution to the squamous subtype
of human PDAC. We targeted macrophages in a ge-
netic PDACmodel using AZD7507, a potent selective
inhibitor of CSF1R. AZD7507 caused shrinkage of es-
tablished tumors and increased mouse survival in
this difficult-to-treat model. Malignant cell prolifera-
tion diminished, with increased cell death and an
enhanced T cell immune response. Loss of macro-
phages rewired other features of the TME, with
global changes in gene expression akin to switching
PDAC subtypes. These changes were markedly
different to those elicited when neutrophils were tar-
geted via CXCR2. These results suggest targeting
the myeloid cell axis may be particularly efficacious
in PDAC, especially with CSF1R inhibitors.
INTRODUCTION
Pancreatic cancer is predicted to be the second most common
cause of cancer death by 2030 (Rahib et al., 2014). The major
reason for this is that, unlike many other cancers, there have
been no significant improvements in survival over the past 30
years. That said, over the last 5 years there has been great
progress in the understanding of pancreatic cancer (both pre-1448 Cell Reports 23, 1448–1460, May 1, 2018 ª 2018 The Authors.
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under way.
Many of these new developments are based on a deep under-
standing of the molecular pathology of pancreatic cancer. The
definition of subtypes and the use of autochthonous mouse
models have allowed modeling of tumor-stroma interaction,
and the metastatic process, in immune competent mice (Gopi-
nathan et al., 2015). Themost studiedmodel is the ‘‘KPC’’ mouse
model of PDAC when KRASG12D and P53R172H are targeted to
the murine pancreas (normally using the Pdx1-Cre) (Hingorani
et al., 2005). Several studies in mice have highlighted the impor-
tance of the stroma, which provides important pro-survival cues
and may impair therapeutic responsiveness (Neesse et al.,
2015).
Human and murine pancreatic ductal adenocarcinoma
(PDAC) is characterized by a significant stroma containing fibro-
blasts, leukocytes, and collagen deposits (Clark et al., 2007;
Korc, 2007). Of the leukocyte populations, macrophages are
the dominant subtype in the tumor microenvironment (TME)
(Noy and Pollard, 2014). Macrophage infiltration correlates with
poor prognosis in many cancer types (Qian and Pollard, 2010),
including PDAC (Bailey et al., 2016; Ino et al., 2013; Knudsen
et al., 2017). Recent studies have shown that targeting factors
in the stroma, for example, hyaluronic acid (HA) (Provenzano
et al., 2012), and LOX (Miller et al., 2015) as well as genetic abla-
tion of genes such as Stat3 (Corcoran et al., 2011) can slow mu-
rine PDAC. Early phase trials investigating some of these con-
cepts are now planned or under way including compounds
targeting HA (NCT02715804, NCT02921022, NCT02910882)
and JAK1 (NCT02646748, NCT02265510). This is not to say
that all stromal elements are tumor promoting, as a number of
studies targeting the stroma have shown that this may accel-
erate tumorigenesis, or at least generate pancreatic tumors
that are less dependent on stromal signals (O¨zdemir et al.,
2014; Rhim et al., 2014).commons.org/licenses/by/4.0/).
Initial studies of immunotherapy using checkpoint inhibitors in
human PDAC are not encouraging; however, preclinical studies
have suggested co-targeting of additional stroma elements with
combinations may improve efficacy. This has been observed in
the autochthonous KPC model when fibroblasts are depleted
(Feig et al., 2013). In addition, we (Steele et al., 2016) and others
(Chao et al., 2016; Stromnes et al., 2014) have shown similar
phenotypes when neutrophils/myeloid-derived suppressor cells
(MDSC) are lost. Experiments using orthotopic transplantable
PDAC models also show similar effects if macrophages are
depleted or polarized to a tumoricidal phenotype (Beatty et al.,
2011; Luheshi et al., 2016; Zhang et al., 2017; Zhu et al., 2014).
Given that both macrophages and neutrophils are targets in
auto-immune and inflammatory diseases, there are a number
of clinic-ready drugs that could be rapidly progressed to clinical
testing in PDAC in combination with checkpoint inhibition. How-
ever, we don’t yet know how different myeloid cell types influ-
ence tumor progression and response to therapy and thus
have little information guiding the optimization of patient selec-
tion and treatment strategies required for successful translation
to the clinic.
Recent genomic analysis suggests that pancreatic cancer can
be divided into 4 different subtypes (Bailey et al., 2016): squa-
mous, ADEX, progenitor, and immunogenic. A more detailed ex-
amination of the genes that contribute to these different sub-
types suggests immunogenic and squamous subtypes show
high expression of macrophage markers. Moreover, a macro-
phage gene expression program is associated with prognosis
in these patients, consistent with a previous study (Knudsen
et al., 2017). Interestingly, in contrast to other cancers, the
‘‘immunogenic’’ subtype does not confer an improved prognosis
providing further evidence that immunotherapy as a single agent
is unlikely to be effective in this disease. A recent study attemp-
ted to align the different subtypes of PDAC frommultiple studies
(TCGA Research Network, 2017). Here, the squamous subtype
we identified was similar to the previously identified ‘‘quasi-
mesenchymal subtype’’ of PDAC (Collisson et al., 2011). Some
debate remains, however, over the ‘‘ADEX’’ or ‘‘Exocrine-like’’
subtype, with a recent TCGA study suggesting this might reflect
‘‘contamination’’ with non-neoplastic tissue (TCGA Research
Network, 2017).
RNA sequencing (RNA-seq) of KPC tumors has allowed them
to be compared with the different human subtypes. Interestingly,
our analysis has shown that there are elements of all the sub-
types within the KPC tumors. One of the hallmarks of the squa-
mous subtype of PDAC are gene programs associated with
squamous differentiation, hypoxia, extracellular matrix and
transforming growth factor b (TGF-b) signaling. Importantly, we
have shown that these are dependent on mutant p53, so mice
that lack p53 or p63 no longer express these gene programs
(unlike the KPC) and show reduced or absent metastasis. The
fact that KPC mice have these multiple subtypes allows us to
see whether any specific subtype is affected by therapeutic
intervention.
Tumor-associated macrophages (TAMs) play an important
role not only in tumor progression and metastasis but also in
resistance to chemotherapy and radiotherapy (De Palma and
Lewis, 2013; Qian and Pollard, 2010). Preclinical models haveelucidated the critical role of TAMs in cancer development, pro-
gression, and metastasis (DeNardo et al., 2011; Mantovani et al.,
2017; Nielsen et al., 2016; Xu et al., 2013). Signaling through the
cellular receptor for CSF1, CSF1R, promotes the differentiation
of myeloid progenitors into populations of monocytes, macro-
phages, dendritic cells, and osteoclasts. Several therapeutic ap-
plications to impair recruitment or to readjust their behavior are
currently being evaluated (Cannarile et al., 2017; Mantovani
et al., 2017).
Given this wealth of preclinical data and the importance of
macrophage signatures in the human PDAC data, we wanted
to address the impact of CSF1R inhibition on established tumors
in the genetic KPC PDAC mouse model and differentiate these
effects from CXCR2 and CCR2 inhibition. Of all interventions
studied, we found that CSF1R inhibition has the most profound
effect causing tumor regression and T cell activation, indepen-
dent of PD1 inhibition. Importantly, loss of macrophages in the
tumor microenvironment significantly altered tumor architecture
both transcriptionally and histologically. Squamous gene
expression programs were downregulated, with marked activa-
tion of ADEX and immunogenic gene programs. Importantly,
ADEX gene expression programs were observed within the tu-
mor cells, thus excluding contribution of non-neoplastic contam-
ination to the gene programs that define the ADEX subtype.
Comparison with CXCR2 inhibition under the same conditions
showed that the active transcriptional programs reflected the
divergent effects of inhibiting specific myeloid cell populations.
RESULTS
Human and Murine Primary PDACs Are Infiltrated by
CSF1R+ Macrophages and Overexpress CSF1 and IL-34
In our previous studies, we found that themacrophage transcrip-
tional signature was high in squamous and immunogenic sub-
types of PDAC and that the macrophage transcriptional gene
program was associated with a poor prognosis (Bailey et al.,
2016). To determine the presence of macrophages in human
PDAC tissues, we used immunohistochemistry (IHC) to stain
for CD68, a transmembrane glycoprotein highly expressed by
human monocytes and tissue macrophages. CD68+ macro-
phages were rarely present in normal pancreas but PDAC con-
tained significant myeloid cell populations (Figure 1A). In the
mouse, F4/80 is expressed by the majority of mature macro-
phages and iswidely used to identify this population using immu-
nostaining. When compared to healthy control pancreas, there
was a prominent infiltration of F4/80 cells in the stroma of
pancreatic tumors of KPC mice especially in macrophages
accumulated around epithelial tumor cells (Figure 1B). We next
measured the expression of colony-stimulating factor-1 receptor
(CSF1R) on TAMs inmurine pancreatic tumors. CSF1R is located
predominantly on myeloid cells and is involved in macrophage
recruitment. Tissues were stained with antibodies against
CSF1R, F4/80 to definemacrophages, and E-cadherin to identify
epithelial tumor cells (Figure 1C). Co-staining of E-cadherin+
epithelial cells, F4/80+ macrophages, and CSF1R confirmed
that the receptor is exclusively expressed on F4/80+ macro-
phages and not on malignant cells (Figure 1C). CSF1R protein
also localized to the stroma in human PDAC biopsies (Figure 1D).Cell Reports 23, 1448–1460, May 1, 2018 1449
(legend on next page)
1450 Cell Reports 23, 1448–1460, May 1, 2018
CSF1R expression was also absent in PDAC tumor cell lines
derived from mouse (Figure S1A) and human (Figure S1B). Tis-
sue samples from KPC mice (Figure S1C) and patients (Fig-
ure S1D) with PDAC were further stained with immunofluores-
cence antibodies to evaluate the presence of CSF1R ligands,
CSF1, and interleukin-34 (IL-34) in the tumor microenvironment.
Patient tissues were stained with antibodies against CD68 for
macrophages, pan-cytokeratin for epithelial tumor cells, and
with either CSF1 or IL-34. Similar to the mouse model (Fig-
ure S1C), IL-34 and CSF1 were present in the human PDAC
microenvironment (Figure S1D). Co-localization indicated that
pancreatic epithelial tumor cells produce both CSF1 and IL-34
in mouse and human. In addition, there was a significant in-
crease of CSF1 in the plasma of PDAC patients and mice
when compared to aged-matched healthy individuals (Figures
S1E and S1F). To confirm that tumor cells express CSF1, we per-
formed ELISA on 3 KPC cell lines and showed high expression
(Figure S1G).
Taken together these results showed significant infiltration of
CSF1R-expressing macrophages in human and mouse pancre-
atic tumors and that the malignant cells were the source of
CSF1R ligands. Importantly, CSF1R was a component of the
macrophage gene expression profile identified in human PDAC
and therefore offered a way to specifically target macrophages
in PDAC (Figure 1E).
Intriguingly, when we assessed CSF1R expression by IHC of
79 PDAC patients, we found that high CSF1R expression was it-
self associated with poor prognosis, and this was particularly
significant in patients with low T cell infiltration, which was not it-
self prognostic (Figure 1F). This is consistent with the expression
of CSF1R across different subtypes of PDAC being high in both
squamous and immunogenic.
Small-Molecule Inhibitor of CSF1R AZD7507 Blocks
CSF1R Phosphorylation and Depletes Macrophages
In Vitro and In Vivo
In order to gain deeper insight into the role of macrophages in
pancreatic cancer, we investigated the therapeutic impact of in-
hibiting myeloid cell recruitment using AZD7507 (Scott et al.,
2013), a small-molecule tight binding ATP-competitive inhibitor
of CSF1R signaling, the structure of which is available at https://
pubchem.ncbi.nlm.nih.gov/compound/25001557. AZD7507 is a
selective and potent inhibitor of CSF1R kinase activity with an
IC50 of 3 nM and negligible activity against other kinases tested
in in vitro kinase assays (Table S1).
Western blotting confirmed that AZD7507 inhibits CSF1-
induced CSF1R phosphorylation in primary bone marrowFigure 1. Human and Mouse PDAC Tumors Are Infiltrated by Macroph
(A) IHC showing pancreas areas of positivity for CD68 in adjacent normal pancre
(B) IHC showing F4/80 staining in murine healthy pancreas and in PDAC tissue.
(C) Immunofluorescence analysis of CSF1R in murine pancreatic tissue. Tissue s
cadherin (red), and with CSF1R (green) and counterstained with DAPI (blue). Sca
(D) IHC showing CSF1R staining in human PDAC tissue. Scale bar, 200 mm.
(E) ClueGO-CluePedia functional network of the human PDACmacrophage gene
(p value <0.01). Network nodes and edges are colored by a specific gene ontolo
(F) Kaplan-Meier analysis of survival post-resection of a cohort of human PDACpa
low or high CD3+ cells, and low or high CSF1R expression in CD3 low patients.
See also Figure S1.derived cells/monocytes (Figure 2A) and blocks downstream
activation of ERK (Figure 2B). In addition, AZD7507 induced
apoptosis of CSF1R-positive wild-type murine bone marrow
cells (Figures 2C and 2D) but did not affect the viability of cells
differentiated from the bone marrow in the presence of CSF1
(Figure S2A). Further, in murine PDAC cells, which did not ex-
press CSF1R (Figure S2B), AZD7507 had no effect on ERK1/2
phosphorylation (Figure S2C) or proliferation (Figure S2D).
In vivo, AD7507 treatment elicited a dose-dependent deple-
tion of macrophages in MDA-MB-231 xenografts, as assessed
by F4/80 IHC, with maximal depletion at 100 mg/kg (Figure 2E).
AZD7507 Depletes Macrophages in Mice and Mediates
Tumor Regression and Increases Survival
Having established 100 mg/kg of AZD7507 as the relevant dose
to achieve macrophage depletion, we studied its activity in the
KPC genetically engineered mouse model of pancreatic cancer
by treating mice with established tumors with AZD7507 (sched-
uling is shown in Figure 3A).
Flow cytometry analysis (Figure S3A) of tumor tissue after
2 weeks of AZD7507 treatment revealed a significant reduction
in the frequency of F4/80+CD11b+ TAMs (Figures 3B and 3C),
with no significant effect on Ly6C+monocytes, CD11c+ dendritic
cells, or Gr1+ cells (Figure 3C). These results were further sup-
ported and quantified by IHC, showing that, at 2 weeks after
treatment, the percentage of F4/80+ TAMs was significantly
reduced (Figure 3D) and accompanied by a relative decrease
in both CSF1R expression and CSF1R+myeloid cells (Figure 3E).
RNA-seq of tumors suggested that the macrophages that re-
mained resembled M1 type, as expression signatures for M1
were relatively enriched in AZD7507-treated mice compared to
vehicle (Figure S3B).
We observed that in vivo administration of AZD7507 caused a
reduction in tumor mass after 2 weeks of treatment (Figure 3F),
and this was confirmed by ultrasound (US) imaging (Figure 3G).
Importantly, this was associated with an increase in overall sur-
vival (Figure 3H). It is important to note that established tumors in
the KPC model are resistant to many agents e.g., gemcitabine,
Mek inhibition, PI3K inhibition, and rapamycin and very few ther-
apies work as single agents (Alagesan et al., 2015; Gopinathan
et al., 2015; Morran et al., 2014; Olive et al., 2009).
CSF1R Inhibition Alters Tumor Cell Proliferation and the
Stromal Microenvironment
In line with the reduction of TAMs after AZD7507 detected by
IHC, Affymetrix mRNA expression array analysis of tumors after
5 days of treatment showed downregulated expression of genesages and Overexpress CSF1R
as and patients diagnosed with PDAC.
Scale bar, 100 mm.
ections from the pancreas of KPC mice were stained with F4/80 (gray) and E-
le bar, 100 mm.
program (GP7) showing genes associated with significant gene ontology terms
gy terms.
tients in terms of low (belowmedian) or high (abovemedian) CSF1R expression,
p values, log rank test, n = 79.
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Figure 2. AZD7507 Is a Potent and Highly
Selective ATP-Competitive Inhibitor of
CSF1R Kinase Activity
(A and B) Bone marrow-derived macrophages
(BMDMs) were cultured with either media or CSF1
at indicated AZD7507 concentrations and protein
lysate analyzed by western blot for pCSF1R
(Tyr697) and (Tyr807), total CSF1R and b-actin (A),
and pERK1/2 (Thr202/Tyr204), total ERK1/2 and
b-actin (B).
(C) Bone marrow cells were cultured with CSF1
at indicated AZD7507 concentrations for 3 and
7 days, and cell growth was assessed by the
WST-1 colorimetric assay. The graph shows the
percentage viability of treated cells. Data are
represented as mean ± SEM for n > 3.
(D) Dead CSF1R positive BMDM cells were
examined using Annexin V+ membrane viability
dye staining (FVD) and detected by flow cyto-
metry when the cells were cultured for 7 days
in vitro with CSF1. The graph shows the
percentage of necrotic (Annexin V+, FVD+,
CSF1R+) cells.
(E) AZD7507-treatedMDA-MB-231 xenograft tumors at day 20were stainedwith an antibody against F4/80 for IHC, andmacrophage numbers were quantified as
percentage of brown pixels. Data are represented as mean ± SEM.
See also Figure S2.characteristic of macrophage infiltration, including Csf1r, Arg1,
Emr1, Mrc1, and Msr1 (Figure S4A). The upregulated genes
were enriched for molecules associated with T cell phenotype
and immune activation, including Cd69, CD8, and Gzma, sug-
gesting an increase in local adaptive immunity (Figure S4B).
We also analyzed the mRNA expression profile of the tumor
following 14 days of treatment with either AZD7507 or vehicle
control. RNA-seq analyses of whole-tumor tissuemRNA expres-
sion revealed 374 downregulated and 453 upregulated genes in
AZD7507-treated tumors compared to controls (Figure 4A). The
list of downregulated genes was enriched for markers involved in
cell-cycle regulation (MKi67, Cdk6, Aurka, and Cdc20), (Fig-
ure S4C) DNA damage response (Lig1, Pcna, Pole, and Pttg1)
(Figure S4D), and hypoxia/metabolism (Hif3a, Anxa, Aldoa, and
Ldha) (Figure S4E).
We previously reported that a hypoxia gene expression signa-
ture correlated with poor prognosis of patients with PDAC
following surgery, and that an important component of that
signature was the collagen cross-linking enzyme LOX (Miller
et al., 2015). We therefore examined changes in the tumormicro-
environment of the KPC mice following AZD7507 treatment. Us-
ing Masson’s Trichrome staining, we observed a decrease in
collagen I staining consistent with degradation of the tumor ma-
trix as early as 5 days post-treatment (Figure 4B). Moreover,
analysis of second harmonic signals generated through multi-
photon microscopy demonstrated that AZD7507 treatment had
a qualitative impact upon collagen deposition in PDAC, with
both the scale and discrete nature of collagen fibrils reduced in
treated specimens (Figure 4C). Fibro-inflammatory stroma is a
hallmark in pancreatic cancer and may play a role in treatment
resistance (Olive et al., 2009). Next, we used immunofluores-
cence to measure the pancreatic fibro-inflammatory stromal
content by assessing alpha-smooth muscle actin (SMA) expres-
sion, a marker of activated fibroblasts. KPC mice treated with1452 Cell Reports 23, 1448–1460, May 1, 2018AZD7507 displayed less prominent alpha-SMA-positive stromal
expansion than in vehicle-treated KPC mice (Figure 4D).
Together, these findings infer that macrophages may favor the
proliferation of tumor cells as well as maintaining their survival. In
addition, the data suggest that macrophages favor higher stro-
mal expression of collagen and this may impair adaptive immune
cells from exerting their effector function, thus enhancing tumor
growth.
It is well established that the cytokine milieu generates an
inflammatory and immunosuppressive microenvironment by
inducing macrophages and Tregs to facilitate tumor progression
(Mantovani et al., 2017). To assess the soluble factors in the
tumor microenvironment, tumors were harvested and protein
lysates were analyzed for cytokine changes. There were signifi-
cant decreases in several potent pro-tumor cytokines including
IL-6 and IL-10 (Figure 4E) and chemokines such as CCL2 and
CCL12 (Figure 4F) in the tumors of the KPC mice treated with
AZD7507 for 14 days.
To evaluate whether the high number of macrophages
present in the tumor microenvironment of the KPC mice
contribute to the production of these cytokines as well as their
capacity to suppress T cells, we removed F4/80+ macro-
phages from tumor cell suspensions obtained from collage-
nase-digested tumors and then cultured the cells from the
tumor in the presence of plate-bound anti-CD3 and soluble
CD28. After 72 hr, cells were stained and analyzed by flow
cytometry. We observed that the frequency of interferon
(IFN)-g, Granzyme B, and Perforin CD3/CD28-activated
CD8+ T cells were increased in the absence of macrophages
when compared to samples where macrophages were present
(Figures 4G and 4H). This suggests that macrophages have a
direct effect on the ability of T cells to become cytotoxic. In
line with this hypothesis, we observed that PD-L1 was highly
expressed on TAMs (Figure 4I).
Figure 3. CSF1R Inhibition Depletes Macrophages, Regresses Tumor Growth, and Prolongs Survival in KPC Mice
(A) Schematic diagram of the experimental setup with an outline summary of the treatment regimen and time points used.
(B) Representative flow cytometry plot of CD11b and F4/80 in live CD45+ cells from KPC tumor of either vehicle or AZD7507-treated mice.
(C) Graph shows quantification of TAMs, Gr1+ cells, Ly6C+ monocytes, and CD11c+ dendritic cells as percentage of total CD45+ cells (data are shown are
mean ± SEM, n > 7, unpaired t test).
(D) IHC showing F4/80+ macrophages in tumors from KPC mice treated as indicated. Graph shows quantification of F4/80 IHC (data are shown as mean, n = 5).
(E) Histogram on right shows representative flow cytometry with numbers showing mean geoMFI data (n = 5 mice per group; isotype control, light gray; vehicle,
dark gray; AZD7507, red). Graph on left shows frequency of CSF1R+ TAMs in tumors of mice treated as indicated (data are shown as mean ± SEM, n = 5).
(F) Gross morphology of tumors and tumor weight in each group after 2 weeks of treatment. (Data shown are mean ± SEM, n > 34, unpaired t test.)
(G) Tumor growth was monitored by high-resolution ultrasound in KPC mice with mean tumor diameters >5 mm before (day 0) and 14 days after treatment with
either vehicle or AZD7507. Quantification of tumor volume in vehicle-treated (n = 7) and AZD7507-treated mice (n = 5).
(H) Kaplan-Meier survival analysis of KPC mice treated with vehicle (n = 6) or AZD7507 (n = 12).
See also Figure S3.
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As shown here, pancreatic tumor macrophages have a signif-
icant immunosuppressive capacity. To determine whether
macrophage ablation would trigger anti-tumor T cell activity in
PDAC tumors, we investigated tumor-infiltrating lymphocytes
in KPC mice treated with AZD7507. Flow cytometry analysis of
tumor-infiltrating T cells in mice treated with AZD7507 showed
significantly increased CD3+ T cells in KPC tumors (Figure S4F).
This increase correlatedwith significant increases in the percent-
ages of CD3+CD4+ T cells and CD3+CD8 cytotoxic T cells (Fig-
ure 4J) but, importantly, no increase of CD4+Foxp3 T regulatory
cells (Treg) (Figure 4K). Indeed, AZD7507 treatment significantly
improved effector (CD4+Foxp3–)-to-Treg ratios (Figure S4G).
Importantly following AZD7507 treatment, all PD-L1+ stroma
cells were depleted suggesting the macrophages as the sole
source of PD-L1 in the stroma (Figure 4L).
CSF1R Inhibition of Macrophage Population Is Distinct
from Inhibition of Other Myeloid Populations
Given the dramatic effect of CSF1R inhibition as a single agent
compared to our previous work on CXCR2 inhibition where effi-
cacy in late-stage tumors was only observed in combination with
anti-checkpoint inhibition (Steele et al., 2016), we wanted to
compare the effect of these inhibitors on tumor gene expression.
We focused on the gene expression signatures that define the
four recently identified human PDAC subtypes, namely, the
‘‘Squamous’’ subtype, associated with poor outcome, ‘‘pancre-
atic progenitor,’’ ‘‘immunogenic,’’ and aberrantly differentiated
endocrine exocrine, or ‘‘ADEX’’ (Bailey et al., 2016). When global
gene expression was examined in our treated KPC tumors,
CSF1R inhibition caused a dramatic increase in the ‘‘ADEX’’
and ‘‘Immunogenic signatures’’ and a decrease in the squamous
signature (Figure 5A). When specific gene programs were exam-
ined, we observed a significantly increased expression of immu-
nogenic programs relating to CD8+ T cells, and B cells (Figures
5B and 5C) supporting our earlier findings (Figures 4H and
S4F). There were also significant increases in gene programs
associated with b-cell development and exocrine pancreas ex-
plaining the switch to ADEX subtype. Again, there was a marked
impact on malignant epithelial cell gene programs, with a clear
reduction in proliferation and programs associated with MYC.
Importantly, we confirmed changes in individual componentsFigure 4. AZD7507 Alters Tumor Microenvironment Composition and F
(A) Signal log2 expression of downregulated (blue) and upregulated (red) genes
portional to the signal log2 intensity. All genes had a false discovery rate (FDR) <
(B) IHC staining of Masson’s Trichrome and Collagen I in tumors of KPC mice tre
(C) Gray-level correlation matrix (GLCM) texture analysis of the second harmonic
as indicated. Mean ± SEM at each distance.
(D) KPC tissue sections from the pancreas of each group were stained against E
terstained with the nuclear stain DAPI (blue). Image represents tissue samples fr
(E and F) Protein lysates were obtained from tumors treated as indicated and were
analysis (Myriad RBM Mouse Inflammation MAO v.1.0 array) (n > 9).
(G and H) Representative flow cytometry analysis (G) and quantification (H) for Gr
(CD3/CD28) cells cultured for 72 hr in the presence or absence of TAMs (n > 4).
(I) Histogram of PD-L1 expression by fluorescence-activated cell sorting (FACS)
(J) Flow cytometry analysis of the CD45+ T cell subsets in the tumor of mice trea
(K) Flow cytometry analysis of the frequency of Foxp3+ Tregs and Foxp3– Effect
values were calculated by Mann-Whitney U test (*p < 0.05, **p < 0.01, and ***p <
(L) RNAscope in site hybridization for PD-L1 in tumors for KPC mice treated with
See also Figures S1 and S4.of the gene programs (Figure S5A) by IHC in treated tumors,
for Notch activation (GP9 -Exocrine), CD8+ T cells (GP8), Tenas-
cin C loss (GP5) (Figure 5D), and CPA1 (GP9) (Figure S5B). The
finding of specific genes associated with the ADEX signature in
tumor cells strongly suggest the ADEX subtype cannot be ex-
plained simply by contaminating acinar and islet tissue, or
ADM surrounding tumors.
We then compared the effect of CSF1R inhibition on global
gene expression programs in KPC tumors, with the effects of
CXCR2 inhibition. CXCR2 inhibition, which, as we previously
showed, primarily deleted neutrophils and MDSCs in KPC tu-
mors (Steele et al., 2016), also caused an increase in immuno-
genic gene programs, but instead of a switch to the ADEX signa-
tures there was a switch to ‘‘progenitor’’ gene programs
(Figure 6). The contrasting effects of CXCR2 inhibition versus
CSF1R inhibition were also evident within the gene programs,
with marked differential expression of genes between the 2
different inhibitions (Figure 6).
We finally analyzed whether genetic loss of CCR2, which is
required for myeloid cell recruitment, would recapitulate the
phenotype of CSF1R inhibition in the KPC model. However, ge-
netic deletion of CCR2 (myeloid cell) had no impact on primary
tumor formation on the KPC model (Figure S6).
DISCUSSION
PDAC is a deadly disease characterized by desmoplastic
stroma. Here, we show that by removing one element of this
stroma, CSF1R positive macrophages, many of the elements
of the tumor stroma can be changed in a way that is beneficial
for therapy. The tumor stroma is switched away from an immu-
nosuppressive environment resulting in a marked increase in
CD8+ effector cells, while markers of a stiff environment were
reduced with changes in collagen (both amount and complexity)
and hypoxia (another marker of poor prognosis in PDAC). These
alterations, alongside the cytokines and growth factors released
by macrophages that will be lacking following CSF1R inhibition,
result in reduced tumor cell proliferation and changes in a num-
ber of tumor cell intrinsic pathways (MYC, metabolism). This
means that, of all the myeloid targeting agents used so far,
CSF1R looks the most promising as a single agent, at least inunction
in vehicle-treated tumors compared with AZD7507. The color intensity is pro-
0.05.
ated for 5 days with either vehicle or AZD7507 (n > 3). Bar, 50 mm.
generation (SHG) signal emitted by PDAC-associated collagen in mice treated
-cadherin (gray) and with a-SMA (red) and F4/80 (green). Tissues were coun-
om a total of at least n = 3 KPC mice per group.
analyzed for cytokine contents usingmultiplex (E), cytokine (F), and chemokine
anzyme B, IFN-g, and Perforin expression in either unstimulated or stimulated
analysis on myeloid subsets as indicated (n = 4).
ted as indicated (n > 10).
or CD4+ T cells in the tumor of mice treated with either vehicle or AZD7507. p
0.001), mean ± SEM.
either vehicle or AZD7507.
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Figure 5. CSF1R Inhibition Results in Significant Reprogramming of Gene Expression Profiles in KPC Mice
(A) Barcode plots showing strong enrichment of PDAC class signatures in either control KPC or KPCmice treatedwith AZD7507. Vertical bars represent signature
genes, and lines represent relative signature enrichment. For example, in the top panel, red vertical bars represent genes significantly expressed in the
Immunogenic class that are enriched in AZD7507-treated KPC tumors. Enrichment is indicated by an ascending line. p < 0.001 in all cases, nR 5.
(B) Boxplots showing the relative enrichment of the indicated gene programs (GP) in AZD7507-treated versus untreated tumor-bearing KPC mice. Boxplots are
annotated by a Kruskal-Wallis p value, nR 5.
(C) Flow cytometry analysis of CD19+ B cells subsets in tumors of mice treated with vehicle (n = 9) or AZD7507 (n = 6).
(D) IHC for Notch ICD, CD8 (arrows indicate positive cells), and Tenascin C confirms upregulation of ADEX and Immunogenic signatures and downregulation of
Squamous signature. Scale bar, 200 mM.
See also Figure S5.this mouse model of PDAC. This is an important concept given
the burgeoning number of potential myeloid target agents that
are either ready for, or have entered clinical trials (e.g., CSF1R,
IL6, JAK/STAT, CXCR2, and CD40).
A number of subtypes of human PDAC have been defined by
global gene expression studies, andwe recently found that by in-
hibiting neutrophil infiltration into KPC PDAC, via CXCR2 target-
ing, we could observe a gene expression changes that resem-
bled switching of subtype (Steele et al., 2016). There has been
much discussion over which signatures come from tumor cells
and what might be stromal signatures. Here again, we have1456 Cell Reports 23, 1448–1460, May 1, 2018found that CSF1R inhibition drives gene expression changes
and a subtype switch, although, strikingly, the changes we
observe in response to macrophage targeting are markedly
different from those we observe when we target neutrophils.
Thus, our data would argue that stromal cells drive the charac-
teristics of gene expression in tumor cells.
Recent work by the Jorgenson laboratory has shown how
important fibroblast-tumor cell interactions are in driving epithe-
lial gene expression programs (Tape et al., 2016). It is interesting
to note here that by altering macrophages we also observe pro-
found differences in markers of cancer-associated fibroblasts
Figure 6. Inhibition of CSF1R Is Not Equivalent to CXCR2 Inhibition
Boxplots showing the relative enrichment of the indicated gene programs (GP)
stratified by treatment as indicated. Boxplots are annotated by a Kruskal-
Wallis p value, nR 5. See also Figure S6.(CAFs), with a striking downregulation of aSMA, tenascin C,
collagen, and tissue stiffness. Precisely how this occurs will be
a focus of future studies, and while we cannot rule out some
direct effects of CSF1R inhibition on CAFs, since a subset of
these express CSF1R at low levels (Kumar et al., 2017; O¨hlund
et al., 2017), it will be of interest to see how different elements
of the stroma reinforce and amplify signals.
Moreover, we and others have previously shown how impor-
tant MYC is in PDAC, with a 50% reduction leading to a strong
suppression of tumorigenesis (Walz et al., 2014). Given CSF1R
inhibition led to a profound reduction in MYC gene programs, it
again suggests a very important paracrine role of the stroma in
modulating key epithelial driver pathways in epithelial cells. It is
important to note that we also have seen clear expression of
ADEX gene programs within epithelial tumor cells, which argues
against the concept that ADEX is a product of contaminating
pancreas.
One interesting open question is the differential dependence
on macrophages in the different human subtypes of PDAC. Asmacrophage density is high in both the squamous/mesenchymal
and the immunogenic subtypes (which have a different prog-
nosis), it will be of interest to study in more detail their respective
macrophage phenotypes. Recent studies have shown a high
heterogeneity of macrophages in human cancer, and there is a
large body of work showing that macrophages have many
different states (e.g., early studies suggesting M1 V M2 macro-
phages) and functions/phenotype (Ostuni et al., 2015). Our
data here show that macrophages in the KPC model, which
aligns with the squamous subtype, express high levels of
PD-L1, and this may in part explain the reversal of immune sup-
pression following CSF1R inhibition. It is tempting to suggest
macrophages in the human immunogenic subtype may be less
immunosuppressive, and therefore more work characterizing
macrophage heterogeneity and function in human PDAC is
required (Denardo et al., 2011).
There are important differences between the effects we
observe here following CSF1R inhibition, and those we found
previously when targeting neutrophils via CXCR2 (Steele et al.,
2016). Here, we show that CSF1R inhibition produces both a
vastly different phenotype but also different mechanistic conse-
quences in terms of inhibiting growth of the primary tumor and
relieving T cell suppression. Therefore, delineating the differ-
ences between inhibition of different myeloid cells is very impor-
tant. Two recent studies confirm and extend our observations on
the very different mechanisms and consequences of inhibiting
different myeloid cell populations. In orthotopic PDAC transplant
models, inhibition of CXCR2 alongside CCR2 improved chemo-
therapeutic efficacy due to a compensatory increase in CXCR2
or CCR2 positive cells if a single inhibitor was used (Nywening
et al., 2017). In a series of syngeneic lines, Kumar et al. (2017)
showed that CSF1R inhibition led to increased production of
granulocyte/neutrophil chemokines from fibroblasts, provoking
their recruitment. Combining inhibition of CXCR2 with CSF1R
stopped the recruitment of these neutrophil/granulocytes and
improved efficacy. It is interesting to note here that in the autoch-
thonous KPC model we did not see such a dramatic increase in
CXCR2 positive cells on treatment with the CSF1R inhibitor.
However, much further work is required in both the scheduling
and combinations of neutrophil, macrophage, and checkpoint
inhibition ahead of clinical trials.
In summary, we have identified a critical and distinct role for
CSF1R positive macrophages in PDAC that should underpin
future clinical trials. Taken together with our previous work, these
preclinical studies suggest that sequential scheduling of treat-
ments that target different myeloid cell populations may be of
benefit in patients with advanced pancreatic cancer.EXPERIMENTAL PROCEDURES
Pancreatic Cancer Tissue Microarray
Tissue microarrays containing 5 cores of resected PDAC from each of 79 adult
patients were obtained from Greater Glasgow and Clyde NHS Biorepository.
Tissue was collected prospectively with local ethical approval (West of Scot-
land Research Ethics Service REC reference number 09/S0704/42) and fully
informed consent. Only histologically proven PDACs with complete clinico-
pathological, follow-up, and recurrence data were included. Kaplan-Meier sur-
vival analysis was used to analyze survival from time of surgery, and log-rank
tests were used to compare length of survival between curves. StatisticalCell Reports 23, 1448–1460, May 1, 2018 1457
significance was set at a p value of <0.05. All statistical analyses were per-
formed using SPSS version 19.0 (version 19.0. Armonk, NY: IBM) Following
IHC, expression was scored using HALO software, either as percentage pos-
itive staining (CSF1R) or as percentage of positive cells (CD3).
Human Pancreatic Tissue and Plasma
All tissues were collected with ethical approval and fully informed consent. Dr.
Anne Schultheis (University Hospital Cologne, Germany) kindly provided hu-
man pancreas tissue slides.
Blood samples were collected under ethical approval (REC05/Q0408/65),
and written informed consent was obtained from all patients. Patients were
selected that had a confirmed diagnosis of unresectable locally advanced or
metastatic stage III–IV PDAC. Blood was collected in anti-coagulant-treated
EDTA vacutainer tubes. Whole blood was transferred to falcon tubes and
centrifuged. The plasma supernatant was collected and aliquot into 1.5-mL
Eppendorf tubes.
IHC and Immunofluorescence
IHC was performed on formalin-fixed paraffin-embedded pancreatic tissue
using standard protocols, whereas immunofluorescence was performed on
formalin-fixed paraffin-embedded (human) and frozen (mouse) pancreatic tis-
sue. For immunofluorescence, slides were mounted using Prolong Gold anti-
fade reagent with DAPI. For antibodies, see Supplemental Experimental
Procedures.
RNAscope
In situ detection of PD-L1 transcripts in formalin-fixed paraffin-embedded
(FFPE) mouse PDAC samples was performed using a PD-L1-specific RNA-
scope assay (Advanced Cell Diagnostics) according to the manufacturer’s
protocol.
Animal Experiments
All animal experiments were performed under Home Office license and
approved by the University of Glasgow Animal Welfare and Ethical Review
Board. Mice were maintained in conventional cages and given access to stan-
dard diet and water ad libitum. Female SCID mice aged 6–8 weeks were ob-
tained from Taconic (Germantown, PA). KPC mice, first described by Hingor-
ani et al. (2005), were bred in house on a mixed background. Mice were
genotyped by Transnetyx (Cordoba, TN, USA). Mice were monitored at least
3 times weekly and culled when exhibiting symptoms of PDAC. For short-
term drug studies, pancreatic malignancy was confirmed by abdominal palpa-
tion. For drug treatments, adult mice of both sexes were randomly assigned to
cohorts. See Supplemental Experimental Procedures for more information.
Cell Culture
KPC-derived murine pancreatic cancer cell line was obtained from Prof David
Tuveson (Cold Spring Harbor, USA). Human PDAC cell lines PANC-1 and MIA
PaCa-2 were purchased from the American Type Culture Collection (ATCC),
and both were derived from male pancreatic duct tumors (Deer et al., 2010).
PDAC cell lines were maintained in complete culture medium with DMEM,
10% v/v fetal bovine serum (FBS), and 1% v/v penicillin/streptomycin under
sterile conditions at 37C and 5% v/v CO2 atmosphere. For information on
bone-marrow-derived macrophages and cell-culture assays, see Supple-
mental Experimental Procedures.
CSF1-R In Vitro Enzyme Assay
Activity of CSF1R kinase domain (aa 568–912 GeneBank ID NM_005211) was
determined using an AlphaScreen assay (PerkinElmer, MA) measuring phos-
phorylation of a biotinylated polyGT peptide (Cisbio).
Western Blotting
Electrophoresis was performed using standard protocols. For more informa-
tion, see Supplemental Experimental Procedures.
Flow Cytometry
Pancreas was collected in ice-cold PBS and washed in Hank’s balanced salt
solution (HBSS) solution before mincing using scalpels. The pieces were then1458 Cell Reports 23, 1448–1460, May 1, 2018incubated in 2 mg/mL collagenase (Sigma) in HBSS with 50 mg/mL DNase
(Sigma) for 20 min at 37oC in a shaker. The almost-dissolved pieces were
then passed through a 70-mm cell strainer and resuspended in flow cytometry
buffer and cells counted. Antibody labeling and flow cytometry were carried
out using standard protocols. For more information, see Supplemental Exper-
imental Procedures.
RNA Extraction
Portions of murine pancreatic tumors were frozen in RNAlater (QIAGEN)
solution until required. RNA extraction was performed using QIAGEN RNeasy
Plus Mini Kit (QIAGEN) and homogenized in a Precellys with ceramic beads
(Stretton scientific). DNA was removed with Turbo DNA-free Kit (Applied
Biosystems).
In short-term treatment studies, 25 mg of frozen pancreatic tissue was dis-
rupted and homogenized by placing them into gentleMACSM tubes with 1 mL
of 4%B-mercaptoethanol (Sigma) in RLT buffer. Samples were processed us-
ing the gentleMACS dissociator set to the RNA-02 program. RNA integrity was
determined using Agilent 2100 Bioanalyzer using the RNA 6000 Nano assay
(Agilent Technology) according to the manufacturer’s protocol.
Affymetrix Analysis
Affymetrix was performed using the GeneChip Hybridization, Wash, and Stain
Kit, GeneChip 30 in vitro transcription (IVT) Express Kit, and the GeneChip
Mouse Genome 430 2.0 Array according to the manufacturer’s instructions
(GeneChip 30 IVT Express Kit, User manual P/N 702646 Rev 8).
Second Harmonic Generation Analysis
Analysis of the deposition and higher-order structure of stromal collagen in
tumors was examined through analysis of second harmonic resonance
produced as a result of multiphoton microscopy. For more information, see
Supplemental Experimental Procedures.
RNA-Seq Analysis
Sequencing reads were mapped to the mouse mm10 genome using the
RNA-seq pipeline implemented by the bcbio-nextgen project (https://
bcbio-nextgen.readthedocs.io/en/latest/). For more information, see Supple-
mental Experimental Procedures.
Statistical Analysis
Kaplan-Meier survival analysis was performed and survival between cohorts
compared using log-rank tests (n = number of mice). Assessment of differ-
ences in average counts between different mice was performed using non-
parametric Mann-Whitney testing and unpaired t tests (n = number of mice).
Analyses were performed using GraphPad Prism software (version 5.0).
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq data reported in this paper is
ArrayExpress: E-MTAB-6620 (https://www.ebi.ac.uk/arrayexpress).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at https://
doi.org/10.1016/j.celrep.2018.03.131.
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